BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3142915)

  • 21. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations].
    De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G
    Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H; Tamura T; Sasaki S; Takebe K
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas.
    Moyse E; Le Dafniet M; Epelbaum J; Pagesy P; Peillon F; Kordon C; Enjalbert A
    J Clin Endocrinol Metab; 1985 Jul; 61(1):98-103. PubMed ID: 2860120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrine and immunohistochemical studies on thyrotropin (TSH)-secreting pituitary adenomas: responses of TSH, alpha-subunit, and growth hormone to hypothalamic releasing hormones and their distribution in adenoma cells.
    Kuzuya N; Inoue K; Ishibashi M; Murayama Y; Koide Y; Ito K; Yamaji T; Yamashita K
    J Clin Endocrinol Metab; 1990 Nov; 71(5):1103-11. PubMed ID: 1699960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A; Sanno N; Tahara S; Osamura YR
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.
    Giusti M; Lomeo A; Monachesi M; Mazzocchi G; Attanasio R; Sessarego P; Mignone D; Del Monte P; Giordano G
    J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone.
    Hofland LJ; van Koetsveld PM; van Vroonhoven CC; Stefanko SZ; Lamberts SW
    J Clin Endocrinol Metab; 1989 Mar; 68(3):613-20. PubMed ID: 2493040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electron microscopical morphometry of pituitary adenomas. Comparison of tumours in acromegaly and hyperprolactinemia.
    Saeger W; Kant P; Caselitz J; Lüdecke DK
    Pathol Res Pract; 1988 Feb; 183(1):17-24. PubMed ID: 3362748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-function correlations of growth hormone or/and prolactin-producing pituitary adenomas: an in vitro study with the reverse hemolytic plaque assay.
    Thodou E; Kontogeorgos G; Kyrodimou E; Salla H; Ramyar L; Vamvassakis E; Piaditis G; Anagnostopoulos N; Tzanis S; Levedis A; Rologis D; Asa SL
    J Endocrinol Invest; 1999 Oct; 22(9):671-80. PubMed ID: 10595830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased bioactivity.
    Beck-Peccoz P; Piscitelli G; Amr S; Ballabio M; Bassetti M; Giannattasio G; Spada A; Nissim M; Weintraub BD; Faglia G
    J Clin Endocrinol Metab; 1986 Apr; 62(4):704-11. PubMed ID: 2419356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolactin presents in all pituitary tumors of acromegalic patients.
    Furuhata S; Kameya T; Otani M; Toya S
    Hum Pathol; 1993 Jan; 24(1):10-5. PubMed ID: 8418010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nitric oxide modulates in vivo and in vitro growth hormone release in acromegaly.
    Cuttica CM; Giusti M; Bocca L; Sessarego P; De Martini D; Valenti S; Spaziante R; Giordano G
    Neuroendocrinology; 1997 Dec; 66(6):426-31. PubMed ID: 9430448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man.
    Masturzo P; De Maria A; Murialdo G; Bonura ML; Zauli C; Polleri A
    J Clin Endocrinol Metab; 1985 Aug; 61(2):378-81. PubMed ID: 4008612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: correlation with GH release.
    Hofland LJ; van Koetsveld PM; Verleun TM; Lamberts SW
    Clin Endocrinol (Oxf); 1989 Jun; 30(6):601-11. PubMed ID: 2512040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The TSH secretion in the human pituitary adenomas.
    Trouillas J; Girod C; Loras B; Claustrat B; Sassolas G; Perrin G; Buonaguidi R
    Pathol Res Pract; 1988 Sep; 183(5):596-600. PubMed ID: 3237550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of pituitary adenoma cell subpopulations from acromegalic patients obtained by Percoll density gradient centrifugation.
    Hofland LJ; van Koetsveld PM; Verleun TM; Lamberts SW
    Acta Endocrinol (Copenh); 1989 Aug; 121(2):270-8. PubMed ID: 2549755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.
    Serri O; Robert F; Comtois R; Jilwan N; Beauregard H; Hardy J; Somma M
    Clin Endocrinol (Oxf); 1987 Oct; 27(4):429-36. PubMed ID: 3124991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-subunit immunoreactivity in plurihormonal pituitary adenomas of patients with acromegaly.
    Kontogeorgos G; Kovacs K; Scheithauer BW; Rologis D; Orphanidis G
    Mod Pathol; 1991 Mar; 4(2):191-5. PubMed ID: 1646455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for the release of a novel pituitary polypeptide (7B2) from the growth hormone-producing pituitary adenoma of patients with acromegaly.
    Natori S; Iguchi H; Nawata H; Kato K; Ibayashi H; Nakagaki H; Chrétien M
    J Clin Endocrinol Metab; 1988 Feb; 66(2):430-7. PubMed ID: 3123513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients.
    De Marinis L; Mancini A; Zuppi P; Fiumara C; Conte G; Sammartano L; Fabrizi ML; Valle D
    Exp Clin Endocrinol Diabetes; 1996; 104(1):67-71. PubMed ID: 8750573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.